Abivax: recruitment begins for Crohn's trial

(CercleFinance.com) - Biotech company Abivax announces that the first patient has been enrolled in its Phase 2b ENHANCE-CD clinical trial (NCT06456593), evaluating obefazimod in Crohn's disease patients.


This milestone brings us closer to our goal of addressing the unmet needs of these patients, by offering them effective treatments that alleviate the constraints of their daily lives, Medical Director Fabio Cataldi said.

The multicenter, double-blind, randomized, placebo-controlled trial will evaluate the efficacy and safety of once-daily obefazimod in adults with moderately to severely active Crohn's disease.


Copyright (c) 2024 CercleFinance.com. All rights reserved.